drugset
drugset / Trial / NCT05048849

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study

NCT05048849 ↗

Phase 2 Completed 274 enrolled Medigen Vaccine Biologics Corp.
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the safety and immunogenicity of MVC-COV1901 vaccine who are generally healthy or with stable pre-existing health conditions and have received 2 doses of Placebo in the main study CT-COV-21

Timeline

Start
2021-07-19
Primary completion
2021-11-08
Completion
2022-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MVC-COV1901 Vaccine — Intramuscular

Indications

No indication recorded.